In September 2023, Penn spinout BlueWhale Bio surfaced with a mission to overhaul cell therapy production. The Philadelphia-based company uncloaked last week with news that it has raised $18 million in seed financing, led by the ventures arm of Danaher Corporation with contributions from Novalis LifeSciences and Marshall Wace.
BlueWhale’s goal is to develop a technology platform and product portfolio that have the potential to bring the benefits of cell therapy to more patients in a way that is quicker and requires lower costs. The company’s scientific team is spearheaded by Carl June, M.D., the Richard W. Vague professor in immunotherapy and James Riley, Ph.D., a professor of microbiology.
Read more about BlueWhale here: